Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Interferon-gamma Reverses Bone Marrow Inhibition Following Hemorrhagic Shock

Interferon-gamma Reverses Bone Marrow Inhibition Following Hemorrhagic Shock Abstract • Hemorrhagic shock has been demonstrated to alter the myelopoietic response to bacterial lipopolysaccharide. Interferongamma has been shown to improve the immune response following experimental shock and injury; however, its effect on myelopoiesis is controversial. This study was performed to determine whether treatment with interferon-gamma will improve the bone marrow response to lipopolysaccharide after hemorrhagic shock. Rats subjected to either shock or a sham procedure were allocated into three groups: (1) control rats received no further treatment; (2) lipopolysaccharide-treated rats received saline for 3 days and then were challenged with lipopolysaccharide to stimulate myelopoiesis; and (3) interferon-treated rats received interferon-gamma (7500 U subcutaneously 1 hour after shock and then every day for 3 days) and lipopolysaccharide as in group 2. Serum colony-stimulating factor levels were measured 6 hours and bone marrow white blood cell count and granulocyte-macrophage colony-forming units (CFU-GM) were measured 24 hours following lipopolysaccharide administration. In sham-treated rats, lipopolysaccharide increased CFU-GM 77% compared with controls. In contrast, treatment with lipopolysaccharide decreased CFU-GM 43% following shock. Treatment with interferon-gamma increased CFU-GM in all animals and reversed the decline in CFU-GM seen in shocked lipopolysaccharide-treated animals. Serum colony-stimulating factor levels were unaffected by either shock or interferon-gamma administration. These data demonstrate that interferon-gamma exerts a stimulatory effect on bone marrow following shock and restores the myelopoietic response to lipopolysaccharide. (Arch Surg. 1991;126:100-103) References 1. Mogensen SC, Vrelizer JL. The interferon-macrophage alliance . Interferon . 1987;8:55-84. 2. Faist E, Mewes A, Strasser T, et al. Alteration of monocyte function following major injury . Arch Surg . 1988;123:287-292.Crossref 3. Livingston DH, Appel SH, Wellhauser SR, Sonnenfeld GS. Depressed interferon-gamma production and monocyte HLA-DR expression after severe injury . Arch Surg . 1988;123:1309-1312.Crossref 4. Livingston DH, Malangoni MA. Interferon-gamma restores immune competence after hemorrhagic shock . J Surg Res . 1988;45:37-43.Crossref 5. Hershman MJ, Polk HC Jr, Pietsch JD, et al. Modulation of infection following trauma by interferon-γ treatment . Infect Immun . 1988;56:2412-2416. 6. Piacibello W, Lu L, Rubin B, Broxmeyer HE. Release of granulocytemacrophage colony stimulating factors from major histocompatibility complex class II antigen–positive monocytes is enhanced by human gamma interferon . Blood . 1985;66:1343-1351. 7. Piacibello W, Lu L, Williams D, et al. Human gamma interferon enhances release from phytohemagglutin-stimulated T4+ lymphocytes of activities that stimulate colony formation by granulocyte-macrophage, erythroid, and multipotential progenitor cells . Blood . 1986;68:1339-1347. 8. Phillip R, Epstein LB. Tumor necrosis factor as an immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin 1 . Nature . 1986;323:86-89.Crossref 9. Boraschi D, Lensini S, Tagliasve A. Interferon-gamma reduces macrophage-suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin 1 production . J Immunol . 1984;133:764-768. 10. Broxmeyer HE, Rubin BY, Juliano L, et al. The HLA-DR restricted action of T-lymphocyte subsets on modulation of release of acidic isoferritininhibitory activity from monocytes is mediated by alpha and gamma interferon, interleukin 1, and transferrin . Blood . 1983;62( (suppl 1) ):131a. 11. Koyama S. Clinical investigation of interferons in the preleukemic state (CML and MDS) . Jpn J Cancer Chemother . 1988;15:1191-1197. 12. Broxmeyer HE, Lu L, Platzer E, et al. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFUGM) progenitor cells . J Immunol . 1983;131:1300-1305. 13. Broxmeyer HE, Cooper S, Rubin BY, Taylor MW. The synergistic influence of human interferon-gamma and interferon-alpha on suppression of hematopoietic progenitor cells is additive with the enhanced sensitivity of these cells to inhibition by interferons at low oxygen tension in vitro . J Immunol . 1985;135:2502-2506. 14. Koyama S, Narita M. In vitro effects of interferon-alpha and interferongamma on hematopoietic progenitor cells in bone marrow . Acta Haematol Jpn . 1988;51:1540-1549. 15. Raefsky EL, Platanias LC, Zoumbox NC, Young NS. Studies of interferon as a regulator of hematopoietic cell proliferation . J Immunol . 1985;135:2507-2512. 16. Naldini A, Fleischmann WR Jr. In vivo myelosuppression by combination interferon treatment: antagonism of MuIFN-gamma and MuIFN-beta myelosuppressive effects . J Biol Response Mod . 1987;6:546-555. 17. Kurzrock R, Talpaz M, Kantarjian H, et al. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma . Blood . 1987;70:943-947. 18. Maluish AE, Urba WJ, Longo DL, et al. The determination of immunologically active dose of interferon gamma in patients with melanoma . J Clin Oncol . 1988;6:434-445. 19. Metcalf D, Johnson GR, Mandel TF. Colony formation in agar by multipotential hematopoietic cells . J Cell Physiol . 1979;98:401-411.Crossref 20. Livingston DH, Gentile PS, Malangoni MA. Bone marrow failure following hemorrhagic shock . Circ Shock . 1990;30:255-264. 21. Peterson V, Hansbrough J, Buerk C, et al. Regulation of granulopoiesis following severe thermal injury . J Trauma . 1983;23:19-24.Crossref 22. Livingston DH, Malangoni MA. An experimental study of susceptibility to infection after hemorrhagic shock . Surg Gynecol Obstet . 1988;168:138-142. 23. Vogel SN, Kaufman EN, Tate MD, Neta R. Recombinant interleukin 1 alpha and recombinant tumor necrosis factor alpha synergize in vivo to induce early endotoxin tolerance and associated hematopoietic changes . Infect Immunol . 1988;56:2650-2657. 24. Ulich TR, Castille JD, Yin S. Tumor necrosis factor exerts dose-dependent effects on erythropoiesis and myelopoiesis in vivo . Exp Hematol . 1990;18:311-315. 25. Madonna GS, Vogel SN. Early endotoxin tolerance is associated with alterations in bone marrow–derived macrophage precursor pools . J Immunol . 1985;135:3763-3771. 26. Ulich TR, Castillo JD, Guo K. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs . Blood . 1989;73:108-110. 27. Kedar E, Reza AR, Giorgi JV, et al. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells . Nat Immun Cell Growth Regul . 1988;7:13-30. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Surgery American Medical Association

Interferon-gamma Reverses Bone Marrow Inhibition Following Hemorrhagic Shock

Livingston, David H.
Archives of Surgery , Volume 126 (1) – Jan 1, 1991
Download PDF
4 pages

Loading next page...
 
/lp/american-medical-association/interferon-gamma-reverses-bone-marrow-inhibition-following-hemorrhagic-yjLAwfDfYm

References (29)

Publisher
American Medical Association
Copyright
Copyright © 1991 American Medical Association. All Rights Reserved.
ISSN
0004-0010
eISSN
1538-3644
DOI
10.1001/archsurg.1991.01410250108018
Publisher site
See Article on Publisher Site

Abstract

Abstract • Hemorrhagic shock has been demonstrated to alter the myelopoietic response to bacterial lipopolysaccharide. Interferongamma has been shown to improve the immune response following experimental shock and injury; however, its effect on myelopoiesis is controversial. This study was performed to determine whether treatment with interferon-gamma will improve the bone marrow response to lipopolysaccharide after hemorrhagic shock. Rats subjected to either shock or a sham procedure were allocated into three groups: (1) control rats received no further treatment; (2) lipopolysaccharide-treated rats received saline for 3 days and then were challenged with lipopolysaccharide to stimulate myelopoiesis; and (3) interferon-treated rats received interferon-gamma (7500 U subcutaneously 1 hour after shock and then every day for 3 days) and lipopolysaccharide as in group 2. Serum colony-stimulating factor levels were measured 6 hours and bone marrow white blood cell count and granulocyte-macrophage colony-forming units (CFU-GM) were measured 24 hours following lipopolysaccharide administration. In sham-treated rats, lipopolysaccharide increased CFU-GM 77% compared with controls. In contrast, treatment with lipopolysaccharide decreased CFU-GM 43% following shock. Treatment with interferon-gamma increased CFU-GM in all animals and reversed the decline in CFU-GM seen in shocked lipopolysaccharide-treated animals. Serum colony-stimulating factor levels were unaffected by either shock or interferon-gamma administration. These data demonstrate that interferon-gamma exerts a stimulatory effect on bone marrow following shock and restores the myelopoietic response to lipopolysaccharide. (Arch Surg. 1991;126:100-103) References 1. Mogensen SC, Vrelizer JL. The interferon-macrophage alliance . Interferon . 1987;8:55-84. 2. Faist E, Mewes A, Strasser T, et al. Alteration of monocyte function following major injury . Arch Surg . 1988;123:287-292.Crossref 3. Livingston DH, Appel SH, Wellhauser SR, Sonnenfeld GS. Depressed interferon-gamma production and monocyte HLA-DR expression after severe injury . Arch Surg . 1988;123:1309-1312.Crossref 4. Livingston DH, Malangoni MA. Interferon-gamma restores immune competence after hemorrhagic shock . J Surg Res . 1988;45:37-43.Crossref 5. Hershman MJ, Polk HC Jr, Pietsch JD, et al. Modulation of infection following trauma by interferon-γ treatment . Infect Immun . 1988;56:2412-2416. 6. Piacibello W, Lu L, Rubin B, Broxmeyer HE. Release of granulocytemacrophage colony stimulating factors from major histocompatibility complex class II antigen–positive monocytes is enhanced by human gamma interferon . Blood . 1985;66:1343-1351. 7. Piacibello W, Lu L, Williams D, et al. Human gamma interferon enhances release from phytohemagglutin-stimulated T4+ lymphocytes of activities that stimulate colony formation by granulocyte-macrophage, erythroid, and multipotential progenitor cells . Blood . 1986;68:1339-1347. 8. Phillip R, Epstein LB. Tumor necrosis factor as an immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin 1 . Nature . 1986;323:86-89.Crossref 9. Boraschi D, Lensini S, Tagliasve A. Interferon-gamma reduces macrophage-suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin 1 production . J Immunol . 1984;133:764-768. 10. Broxmeyer HE, Rubin BY, Juliano L, et al. The HLA-DR restricted action of T-lymphocyte subsets on modulation of release of acidic isoferritininhibitory activity from monocytes is mediated by alpha and gamma interferon, interleukin 1, and transferrin . Blood . 1983;62( (suppl 1) ):131a. 11. Koyama S. Clinical investigation of interferons in the preleukemic state (CML and MDS) . Jpn J Cancer Chemother . 1988;15:1191-1197. 12. Broxmeyer HE, Lu L, Platzer E, et al. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFUGM) progenitor cells . J Immunol . 1983;131:1300-1305. 13. Broxmeyer HE, Cooper S, Rubin BY, Taylor MW. The synergistic influence of human interferon-gamma and interferon-alpha on suppression of hematopoietic progenitor cells is additive with the enhanced sensitivity of these cells to inhibition by interferons at low oxygen tension in vitro . J Immunol . 1985;135:2502-2506. 14. Koyama S, Narita M. In vitro effects of interferon-alpha and interferongamma on hematopoietic progenitor cells in bone marrow . Acta Haematol Jpn . 1988;51:1540-1549. 15. Raefsky EL, Platanias LC, Zoumbox NC, Young NS. Studies of interferon as a regulator of hematopoietic cell proliferation . J Immunol . 1985;135:2507-2512. 16. Naldini A, Fleischmann WR Jr. In vivo myelosuppression by combination interferon treatment: antagonism of MuIFN-gamma and MuIFN-beta myelosuppressive effects . J Biol Response Mod . 1987;6:546-555. 17. Kurzrock R, Talpaz M, Kantarjian H, et al. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma . Blood . 1987;70:943-947. 18. Maluish AE, Urba WJ, Longo DL, et al. The determination of immunologically active dose of interferon gamma in patients with melanoma . J Clin Oncol . 1988;6:434-445. 19. Metcalf D, Johnson GR, Mandel TF. Colony formation in agar by multipotential hematopoietic cells . J Cell Physiol . 1979;98:401-411.Crossref 20. Livingston DH, Gentile PS, Malangoni MA. Bone marrow failure following hemorrhagic shock . Circ Shock . 1990;30:255-264. 21. Peterson V, Hansbrough J, Buerk C, et al. Regulation of granulopoiesis following severe thermal injury . J Trauma . 1983;23:19-24.Crossref 22. Livingston DH, Malangoni MA. An experimental study of susceptibility to infection after hemorrhagic shock . Surg Gynecol Obstet . 1988;168:138-142. 23. Vogel SN, Kaufman EN, Tate MD, Neta R. Recombinant interleukin 1 alpha and recombinant tumor necrosis factor alpha synergize in vivo to induce early endotoxin tolerance and associated hematopoietic changes . Infect Immunol . 1988;56:2650-2657. 24. Ulich TR, Castille JD, Yin S. Tumor necrosis factor exerts dose-dependent effects on erythropoiesis and myelopoiesis in vivo . Exp Hematol . 1990;18:311-315. 25. Madonna GS, Vogel SN. Early endotoxin tolerance is associated with alterations in bone marrow–derived macrophage precursor pools . J Immunol . 1985;135:3763-3771. 26. Ulich TR, Castillo JD, Guo K. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs . Blood . 1989;73:108-110. 27. Kedar E, Reza AR, Giorgi JV, et al. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells . Nat Immun Cell Growth Regul . 1988;7:13-30.

Journal

Archives of Surgery – American Medical Association

Published: Jan 1, 1991

There are no references for this article.